| 1. |
- Andersson, Maria, et al.
(författare)
-
The effect of snuff (smokeless tobacco) on disease activity and function in rheumatoid arthritis : experiences from the Better Anti-Rheumatic FarmacOTherapy, a longitudinal multicenter study on early rheumatoid arthritis.
- 2013
-
Ingår i: Journal of clinical rheumatology. - Philadelphia, PA : Lippincott Williams & Wilkins. - 1076-1608 .- 1536-7355. ; 19:1, s. 14-18
-
Tidskriftsartikel (refereegranskat)abstract
- BACKGROUND: It is not known whether snuff (moist smokeless tobacco) affects disease activity in rheumatoid arthritis (RA).OBJECTIVE: This study aims to study the effect of snuff on disease activity and function in Swedish patients with early RA.METHODS: Between 1992 and 2005, 2800 adult patients were included in the Better Anti-Rheumatic FarmacOTherapy (BARFOT) early RA study in Sweden. Disease Activity Score 28 joints (DAS28), Health Assessment Questionnaire, visual analog scale for general health, and drug treatment were registered at inclusion and at follow-up after 1, 2, and 5 years. European League Against Rheumatism response and remission criteria were applied at 1 year. In 2010, a self-completed postal questionnaire was sent to 2102 patients in the BARFOT study enquiring about lifestyle factors such as smoking and use of snuff. Three controls for each patient using snuff were identified.RESULTS: Fifty-one patients who used snuff were identified, together with 145 controls. When we adjusted for socioeconomic class, disease duration, and previous antirheumatic medication, the snuff users had lower DAS28 values at up to 6 months of follow-up than patients who had never smoked, and they had lower DAS28 values than previous smokers at up to 2 years of follow-up. No effect of snuff use on European League Against Rheumatism response was seen at up to 1 year.CONCLUSIONS: Snuff users initially had lower DAS28 levels than never smokers and previous smokers. Copyright © 2013 by Lippincott Williams & Wilkins.
|
|
| 2. |
|
|
| 3. |
- Kling, A, et al.
(författare)
-
Sepsis as a possible adverse drug reaction in patients with rheumatoid arthritis treated with TNF alpha antagonists
- 2004
-
Ingår i: Journal of clinical rheumatology. - 1076-1608 .- 1536-7355. ; 10, s. 119-122
-
Tidskriftsartikel (refereegranskat)abstract
- Background: Clinical improvement during the treatment of rheumatoid arthritis (RA) with the TNFalpha antagonists has been well documented. Our knowledge of uncommon adverse drug reactions (ADRs) with these new drugs is more restricted. Concerns have been raised that these types of drugs could cause an increased frequency of infections, and already existing infections are named as contraindications in the product labels. Methods: in Sweden, it is compulsory for healthcare professionals with permission to prescribe drugs to report suspected ADRs to the regulatory authority, the Medical Product Agency (MPA). At the 6 regional centers that are established in Sweden, a preliminary causality assessment is made and the data is transferred online to a database. Results: Between January 1, 1999, and June 30, 2003, 29 cases of sepsis were reported as suspected adverse effects caused by drugs. Seventeen of these cases concerned TNFa antagonists. The MPA has received 3 reports of septicemia in patients from Northern Sweden treated with the TNFa antagonist etanercept. In submitting these reports, factors that can contribute to Susceptibility and to more fatal Courses of serious infections are taken into consideration. Demographic and pharmaceutical factors as well as risks from predisposing conditions are discussed in connection with the cases in this report. Conclusion: There is a need for more information to physicians to be aware of sepsis as a possible and serious ADR during treatment with TNF antagonists, and that patients with predisposing diseases or those who do not regularly visit their rheumatologist could be at higher risk.
|
|
| 4. |
|
|
| 5. |
|
|
| 6. |
|
|
| 7. |
|
|
| 8. |
|
|
| 9. |
- Wollheim, Frank
(författare)
-
Scleroderma renal crisis: the sword of damocles.
- 2004
-
Ingår i: Journal of Clinical Rheumatology. - : Ovid Technologies (Wolters Kluwer Health). - 1536-7355 .- 1076-1608. ; 10:5, s. 234-235
-
Tidskriftsartikel (refereegranskat)
|
|
